research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
Search
for
Sort by
Research
180-210 / 1000+ results research 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
research Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
research Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1
Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
research JAK inhibition decreases the autoimmune burden in Down syndrome
JAK inhibition may help manage autoimmune conditions in Down syndrome.
research 5α-Reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives
Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
research Short-term malignancy risk of JAK inhibitors in severe alopecia areata: a multicenter cohort study
JAK inhibitors do not increase cancer risk in severe alopecia areata compared to traditional treatments.
research Janus kinase inhibitors for alopecia areata: a review of clinical data
JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.
research Hair for the Long Haul: Alopecia Areata Cases and Considerations
JAK inhibitors are effective for long-term management of alopecia areata.
research Role of janus kinase inhibitors in the treatment of alopecia areata
Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
research The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
JAK inhibitors show promise in treating skin conditions like eczema, hair loss, and vitiligo but need more safety research.
research JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
research Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment
Infections during JAK inhibitor treatment for alopecia areata are usually manageable and rarely stop treatment permanently.
research Janus Kinase Inhibitors for Alopecia Areata
JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
research JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series
JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
research Alopecia areata universalis nach Sitagliptin-Einnahme
A patient's hair loss may be linked to their diabetes medication, Sitagliptin.
research Refractory alopecia in lupus treated with tofacitinib — a case-based review
Tofacitinib helped regrow hair in a lupus patient with alopecia.
research Design of a gelatin microparticle-containing self-microemulsifying formulation for enhanced oral bioavailability of dutasteride
The new formulation improves dutasteride's absorption when taken orally.
research Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo
Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
research JAK Inhibitors in Down Syndrome: Alopecia Areata Resolution and Vitiligo Improvement with Baricitinib
Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.
research Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review
These new skin treatments are safer and more effective with minimal side effects.
research The role of janus kinases in the treatment of autoimmune skin diseases
Janus kinase inhibitors show promise in treating autoimmune skin diseases.
research Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.
research LB793 A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
research Recalcitrant lichen planopilaris treated with upadacitinib: a case series
Upadacitinib may effectively treat resistant lichen planopilaris.
research Emerging Topical and Systemic JAK Inhibitors in Dermatology
JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.
research Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
research Efficacy of Janus kinase inhibitors in adult patients with alopecia areata
Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.
research Clinical positioning and future prospects of JAK inhibitors in alopecia areata
JAK inhibitors are effective for severe alopecia areata but need better strategies for long-term use and personalized treatment.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.